Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytokinetics 350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 USA

www.cytokinetics.com Employees: 423 P: 650-624-3000 F: 650-624-3010

Description:

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.

Key Statistics

Overview:

Market Capitalization, $K 5,884,178
Enterprise Value, $K 5,839,618
Shares Outstanding, K 118,014
Annual Sales, $ 7,530 K
Annual Net Income, $ -526,240 K
Last Quarter Sales, $ 460 K
Last Quarter Net Income, $ -160,550 K
EBIT, $ -524,630 K
EBITDA, $ -512,740 K
60-Month Beta 0.78
% of Insider Shareholders 3.40%
Float, K 114,002
% Float 96.60%
Short Volume Ratio 0.51

Growth:

1-Year Return 62.26%
3-Year Return 27.75%
5-Year Return 415.62%
5-Year Revenue Growth -76.10%
5-Year Earnings Growth -179.49%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.36 on 11/06/24
Next Earnings Date N/A
Earnings Per Share ttm -5.38
EPS Growth vs. Prev Qtr -3.82%
EPS Growth vs. Prev Year -0.74%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 06/25/13

CYTK Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -50.21%
Profit Margin % -6,988.58%
Debt/Equity -7.52
Price/Sales 800.71
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.12
Interest Coverage -8.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar